Editorials
Therapeutic Hypothermia for Preterm Infants with Hypoxic-Ischemic Encephalopathy: How Do We Move Forward?

https://doi.org/10.1016/j.jpeds.2016.12.074Get rights and content

References (8)

There are more references available in the full text version of this article.

Cited by (10)

  • Behavioral and neuroanatomical outcomes in a rat model of preterm hypoxic-ischemic brain Injury: Effects of caffeine and hypothermia

    2018, International Journal of Developmental Neuroscience
    Citation Excerpt :

    Similarly, there are no published rigorous clinical studies of hypothermia as therapy for human infants less than 36 weeks gestation age as far as we are aware, with the exception of a small-scale retrospective study of preterm infants with a GA of 34–35 weeks in which outcomes were compared to term infants. These authors found that cooling at this age was associated with 20% of preterm infants not completing the cooling period, as well as increased hyperglycemia, increased death, and injury primarily in the white matter compared to more gray matter injury in term infants (Laptook, 2017; Rao et al., 2017). Another planned cool-cap study of infants between 32 and 35 weeks GA was halted at an enrollment of 4 infants, possibly due to safety issues and adverse effects (NCT00620711; Walsh, W. (PI), Vanderbilt University).

  • Acute and long-term NCX activation reduces brain injury and restores behavioral functions in mice subjected to neonatal brain ischemia

    2018, Neuropharmacology
    Citation Excerpt :

    These findings could further explain the long-lasting protection of neurounina and, more in general, of other potential NCX activators in this pathology for which therapeutic options are limited. Indeed, the only approved treatment for neonatal hypoxia is hypothermia that can be applied only in specialized medical centers (Laptook, 2017). In addition, hypothermia may be associated with a broad spectrum of side effects that may be more prominent when applied to preterm compared with term infants.

View all citing articles on Scopus

The author serves as Co-PI for ClinicalTrials.gov: NCT01793129. The author declares no conflicts of interest.

View full text